Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or

• Status: Completed
• Trial end date: 2015-04-28

Summary

The primary objective of the study is to evaluate the safety of idelalisib in combination with an anti-CD20 monoclonal antibody (mAb), a chemotherapeutic agent, a mammalian target of rapamycin (mTOR) inhibitor, a protease inhibitor, an antiangiogenic agent, and/or an immunomodulatory agent in participants with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (NHL), mantle cell lymphoma (MCL), or chronic lymphocytic leukemia (CLL).

• Phase: Phase 1

Details

• Lead Sponsor: Gilead Sciences
• Treatments: Antibodies, Monoclonal; Antineoplastic Agents; Bendamustine Hydrochloride; Bortezomib; Chlorambucil; Everolimus; Fludarabine; Fludarabine phosphate; Idelalisib; Immunologic Factors; Lenalidomide; Ofatumumab; Rituximab; Sirolimus; Thalidomide; Vidarabine